Retatrutide

Retatrutide is a cutting-edge investigational peptide designed to target multiple pathways involved in metabolism and weight regulation. As a novel triple agonist (GLP-1, GIP, and glucagon receptors), it has shown powerful effects on fat loss, appetite control, metabolic health, and overall body composition optimization. Retatrutide represents the next generation of peptide therapies for individuals seeking sustainable weight management and improved metabolic function.

Benefits:

• Supports significant fat loss and body recomposition
• Enhances satiety and reduces cravings
• Improves insulin sensitivity and blood glucose regulation
• May support lean muscle preservation during weight loss
• Promotes sustained metabolic improvements beyond weight reduction

Dosing:

Typical Starting Dose: 2 mg subcutaneously once weekly
• Titration: Gradually increase to 4 mg–8 mg weekly over 4–8 weeks based on tolerance and clinical response
• Maintenance Dose: Often stabilized at 6–8 mg weekly depending on individual goals and side effect profile
• Administration: Subcutaneous injection into the abdomen, thigh, or upper arm
• Important: Always titrate slowly to minimize gastrointestinal side effects

Potential Adverse Effects:

• Nausea, especially during initial titration phase
• Decreased appetite (expected and desired for most users)
• Constipation or mild GI upset
• Rare: Injection site irritation, headache, dizziness
• Hypoglycemia risk is low but may occur if used with other glucose-lowering agents

Most side effects are mild and tend to decrease with continued use and proper titration.

NOTE: This is not medical advise. All peptides are for research purposes only.